Geovax Labs, INC Form 4 insider transactions

GeoVax Labs Director John N. Spencer Jr. acquired 10,000 shares of common stock at $0.5498 per share, increasing his direct beneficial ownership to 21,402 shares.

GeoVax Labs' Chief Medical Officer, Kelly T. McKee Jr., acquired 1,107 shares of common stock, increasing his direct beneficial ownership.

GeoVax Labs, Inc. Director Nicole Lemerond has reported the grant of 10,000 stock options with an exercise price of $2.48, contingent on the recently approved 2025 Stock Incentive Plan.

GeoVax Labs, Inc. Director and 10% Owner Randal Chase has reported the acquisition of 10,000 stock options, deemed granted on June 5, 2025, following shareholder approval of the company's 2025 Stock Incentive Plan.

GeoVax Labs, Inc. Director Dean G. Kollintzas was granted 10,000 stock options with an exercise price of $2.48, following shareholder approval of the company's 2025 Stock Incentive Plan.

GeoVax Labs, Inc. Director Robert T. McNally was granted 10,000 stock options with an exercise price of $2.48, contingent upon and effective from the shareholder approval of the 2025 Stock Incentive Plan on June 5, 2025.

GeoVax Labs, Inc. Director Jayne Morgan has reported the acquisition of 10,000 stock options with an exercise price of $2.48, following shareholder approval of the company's 2025 Stock Incentive Plan.

GeoVax Labs, Inc. Director John N. Spencer Jr. was granted 10,000 stock options at an exercise price of $2.48, contingent on stockholder approval of the 2025 Stock Incentive Plan.

GeoVax Labs, Inc.'s Chief Scientific Officer, Mark J. Newman, was granted 70,000 stock options with an exercise price of $2.48, following stockholder approval of the 2025 Stock Incentive Plan.

GeoVax Labs, Inc.'s Chief Medical Officer, Kelly T. McKee Jr., was granted 70,000 stock options with an exercise price of $2.48, contingent on and following shareholder approval of the 2025 Stock Incentive Plan.

GeoVax Labs, Inc. VP of Business Development, John W. Sharkey, was granted 70,000 stock options at an exercise price of $2.48, following shareholder approval of the 2025 Stock Incentive Plan.

GeoVax Labs, Inc. CFO Mark Reynolds has reported the acquisition of 70,000 stock options with an exercise price of $2.48, granted under the company's 2025 Stock Incentive Plan.

GeoVax Labs, Inc. CEO and Director David A. Dodd was granted 185,500 stock options with an exercise price of $2.48, following shareholder approval of the 2025 Stock Incentive Plan on June 5, 2025.

Director John N. Spencer Jr. recently purchased 10,000 shares of GeoVax Labs, Inc. at $0.98 per share, increasing his direct holdings.

John W. Sharkey, VP of Business Development at GeoVax Labs, Inc., reports purchasing 6,000 shares of common stock at $0.99 per share on April 10, 2025.

GeoVax Labs CEO David Dodd purchased 10,000 shares of the company's common stock at a price of $1.08 per share on April 1, 2025.

GeoVax Labs CFO Mark Reynolds reported purchasing 6,800 shares of common stock at $1.0799 per share on March 31, 2025.

GeoVax Labs CEO, David A. Dodd, reports the acquisition of stock options.

Kelly T. McKee Jr., Chief Medical Officer of GeoVax Labs, Inc., reports the acquisition of stock options.

Mark J Newman, Chief Scientific Officer of GeoVax Labs, Inc., reports the acquisition of stock options.

Mark Reynolds, CFO of GeoVax Labs, Inc., reports the acquisition of stock options.

John W. Sharkey, VP of Business Development at GeoVax Labs, Inc., reports the acquisition of stock options.

Director Randal D. Chase acquired 8,050 stock options in GeoVax Labs, Inc. on August 12, 2024.

Dean G. Kollintzas, a director of GeoVax Labs, Inc., acquired stock options on August 12, 2024.

Director Nicole Lemerond reports acquisition of stock options in GeoVax Labs, Inc.

Robert T. McNally, a director of GeoVax Labs, Inc., acquired 8,050 stock options on August 12, 2024.

Director Jayne Morgan acquired 8,050 stock options in GeoVax Labs, Inc. on August 12, 2024.

John N. Spencer Jr., a director at GeoVax Labs, Inc., acquired 8,050 stock options on August 12, 2024.

GeoVax Labs' CEO, David Dodd, purchased 8,000 shares of the company's common stock at a price of $1.95 per share on August 9, 2024.